MARK ROSEN: Open Payments
NPI 1588101091 · BERKLEY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,638 in 119 payments from 23 companies in 2025. Trend: 2023 $6,267 · 2024 $3,892 · 2025 $2,638
Food & beverage: $2,623Education: $15
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 49 | $1,088 |
| Gilead Sciences, Inc. | 26 | $640 |
| ABBVIE INC. | 8 | $157 |
| AstraZeneca Pharmaceuticals LP | 7 | $123 |
| Napo Pharmaceuticals Inc | 4 | $82 |
| Merck Sharp & Dohme LLC | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Lilly USA, LLC | 3 | $52 |
| PFIZER INC. | 2 | $42 |
| Corcept Therapeutics | 1 | $33 |
Products named: DOVATO, APRETUDE, CABENUVA, VRAYLAR, AIRSUPRA, REXULTI, Mytesi, Biktarvy.
Industry payments across MI — which companies pay providers there.
